Get notified when SNDX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SNDX Syndax Pharmaceuticals Inc 8-K

Syndax raises $250M through convertible notes at 35% premium to fund R&D and commercialization

Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

  • high

    Syndax issued $250M of 2.25% convertible senior notes due 2031 in a private placement, netting approximately $243M after fees. Funds will support working capital, R&D, commercialization activities, and business development.

  • high

    Notes convert at $24.76 per share (35% premium to June 3 stock price), potentially issuing up to 13.6M shares. Initial conversion rate is 40.39 shares per $1,000 principal, subject to anti-dilution adjustments.

    Item 1.01 & 3.02 verify on EDGAR →
  • medium

    Company cannot redeem notes before June 20, 2029. After that date, redemption allowed only if stock trades above 130% of conversion price for 20 of 30 consecutive trading days.

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ISNR 10-Q) is open in full — no account needed.

Partner

Trade SNDX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify